JP2009545619A - 化学療法誘発神経障害の治療に寄与するための方法および医薬製剤 - Google Patents

化学療法誘発神経障害の治療に寄与するための方法および医薬製剤 Download PDF

Info

Publication number
JP2009545619A
JP2009545619A JP2009523049A JP2009523049A JP2009545619A JP 2009545619 A JP2009545619 A JP 2009545619A JP 2009523049 A JP2009523049 A JP 2009523049A JP 2009523049 A JP2009523049 A JP 2009523049A JP 2009545619 A JP2009545619 A JP 2009545619A
Authority
JP
Japan
Prior art keywords
cisplatin
pharmaceutical formulation
administration
treatment
retepurinim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009545619A5 (enExample
Inventor
ガル レディー，
ドルラ ミレジョフスキー，
ルイージ レナーズ，
Original Assignee
スペクトラム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スペクトラム ファーマシューティカルズ インコーポレイテッド filed Critical スペクトラム ファーマシューティカルズ インコーポレイテッド
Publication of JP2009545619A publication Critical patent/JP2009545619A/ja
Publication of JP2009545619A5 publication Critical patent/JP2009545619A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009523049A 2006-08-01 2007-08-01 化学療法誘発神経障害の治療に寄与するための方法および医薬製剤 Withdrawn JP2009545619A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82108206P 2006-08-01 2006-08-01
PCT/US2007/075008 WO2008017000A2 (en) 2006-08-01 2007-08-01 Methods and pharmaceutical preparations for contributing to the treatment of chemotherapy-induced neuropathy

Publications (2)

Publication Number Publication Date
JP2009545619A true JP2009545619A (ja) 2009-12-24
JP2009545619A5 JP2009545619A5 (enExample) 2011-09-22

Family

ID=38744846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523049A Withdrawn JP2009545619A (ja) 2006-08-01 2007-08-01 化学療法誘発神経障害の治療に寄与するための方法および医薬製剤

Country Status (12)

Country Link
EP (1) EP2046335A2 (enExample)
JP (1) JP2009545619A (enExample)
KR (1) KR20090047501A (enExample)
CN (1) CN101657199A (enExample)
BR (1) BRPI0715504A2 (enExample)
CA (1) CA2659477A1 (enExample)
IL (1) IL196824A0 (enExample)
MX (1) MX2009001116A (enExample)
NO (1) NO20090279L (enExample)
RU (1) RU2009107123A (enExample)
WO (1) WO2008017000A2 (enExample)
ZA (1) ZA200900728B (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002004448A2 (en) * 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
BRPI0715504A2 (pt) 2014-05-06
EP2046335A2 (en) 2009-04-15
IL196824A0 (en) 2009-11-18
RU2009107123A (ru) 2010-09-10
MX2009001116A (es) 2009-02-10
CA2659477A1 (en) 2008-02-07
KR20090047501A (ko) 2009-05-12
WO2008017000A3 (en) 2008-03-20
WO2008017000A8 (en) 2009-04-30
ZA200900728B (en) 2010-03-31
CN101657199A (zh) 2010-02-24
NO20090279L (no) 2009-02-26
WO2008017000A2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US6610699B2 (en) Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
JP5216769B2 (ja) 炎症性疾患の処置
DE69326014T2 (de) Dithiocarbamate zur behandlung von atheroskerosis und weiteren kardiovasculären und entzündlichen erkrankungen
DE69636308T2 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
US20080214569A1 (en) Use of phosphatases to treat tumors overexpressing N-CoR
EP1986619A2 (en) Use of phosphatases to treat tumors overexpressing n-cor
WO2009102021A1 (ja) 骨髄由来幹細胞、前駆細胞機能賦活による網膜疾患治療
EA039629B1 (ru) Фармацевтическая комбинация, содержащая селективный агонист рецептора s1p1
JP2005519906A (ja) インスリン抵抗性の処置のためのコリンエステラーゼアンタゴニストの使用
DE102020116980A1 (de) Verwendung von Co-Enzym-Antagonisten zur Stoffwechselverlangsamung
KR20170086058A (ko) 이부딜라스트와 릴루졸의 배합물 및 이의 사용방법
DE102007033359B4 (de) Verwendung eines Granulins oder einer Granulin-ähnlichen Verbindung zur Therapie oder Prophylaxe von chronischen Schmerzen
BRPI0613010A2 (pt) uso de composto ou de enantiâmero ou sal ou Éster farmaceuticamente aceitÁvel do mesmo para tratar epileptogÊnese, composiÇço farmacÊutica e kit
WO2012104355A1 (de) Antivirales mittel enthaltend rekombinante mistellektine
US7238718B2 (en) Method for treating myolytic disease and method for screening antimyolytic agent
CN101657199A (zh) 帮助治疗化学疗法诱导的神经病的方法和药物制剂
US12252522B2 (en) Myokines for treating cell proliferative and metabolic diseases and disorders
US20250205265A1 (en) Asperuloside as an agent for improving vascular and metabolic function in obesity: role of nrf2 activation
EP1465616B1 (en) Treatment of statin side effects using uridine derivatives
CN113677202A (zh) 靶向线粒体的异缩酮/isolevuglandin清除剂
RU2523792C9 (ru) Лекарственное средство для лечения туберкулеза
EP2229943B1 (fr) Composé pour son utilisation dans le traitement des neuropathies périphériques
Porter et al. Effect of low dose intra-arterial reserpine on vascular wall norepinephrine content
JP2026510893A (ja) 神経系障害を治療するための方法
DE4442257A1 (de) Sparsomycin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100715

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20111118

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20111206